The Medicines Company (MDCO) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($2.64 million) and the uptick to downtick ratio was 0.31. The transaction value on upticks was $1.17 million and on downticks, the transaction value was $3.81 million. The transaction value of block trades during downticks was $1.63 million. The money flow was negative ($1.63 million), indicating the traders were booking profit on the price strength. The Medicines Company (MDCO) rose $0.33 at $37.34, during intraday Monday , a rise of 0.89% over the previous days close.
The Medicines Company has dropped 3.34% in the last five trading days, however, the shares have posted positive gains of 3.21% in the last 4 weeks. The Medicines Company is up 4.57% in the last 3-month period. Year-to-Date the stock performance stands at -0.16%.
The Medicines Company (NASDAQ:MDCO): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $37.00 and $36.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $37.42. The buying momentum continued till the end and the stock did not give up its gains. It closed at $37.28, notching a gain of 0.73% for the day. The total traded volume was 364,542 . The stock had closed at $37.01 on the previous day.
In a related news, The director, of Medicines Co /De, Shigeta Hiroaki had unloaded 3,849 shares at $38.5 per share in a transaction on July 11, 2016. The total value of transaction was $148,187. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
The Medicines Company is a global biopharmaceutical company. The Companys marketed products are: Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Minocin (minocycline) for injection, Orbactiv (oritavancin), PreveLeak and Recothrom Thrombin topical (Recombinant). The Companys products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development, including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States, cangrelor, IONSYS (fentanyl iontophoretic transdermal system), Raplixa, formerly referred to as Fibrocaps, and RPX-602. The Companys four research and development product candidates include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Company also develops ABP-700, an intravenous anesthetic, which is in Phase I of clinical studies.